脑白质疏松患者肾功能不全与血浆同型半胱氨酸的相关性研究

doi:10.3969/j.issn.1673-5765.2019.02.004

摘要/Abstract

摘要：

目的探讨脑白质疏松（leukoaraiosis，LA）合并肾功能不全与血浆Hcy水平的相关性。方法选取LA患者作为研究对象，依据病史及肾功能检测指标将患者分为肾功能不全组（观察组）和肾功能正常组（对照组）。记录患者Cr、BUN、UA、Hcy、HbA1c、TC、LDL-C等生化指标水平，并以 Fazekas评分量表完成LA严重程度评分。对比2组生化指标水平，并对肾功能不全的可能影响因素进行多因素分析。对生化指标、肾功能及LA进行相关性分析。结果共入组186例患者，其中对照组112例，观察组74例。①与对照组相比，观察组B U N水平（P =0.001）、Cr水平（P =0.000）、UA水平（P =0.000）、Hcy水平（P =0.000）升高，差异有统计学意义；观察组Fazekas评分较对照组升高，差异有统计学意义（P =0.04）；②相关分析显示，血浆 Hcy水平与Fazekas总评分（r =0.202，P =0.027）、Cr水平（r =0.458，P＜0.001）、UA水平（r =0.229， P =0.010）、BUN水平（r =0.178，P =0.046）正相关；③多因素Logistic回归分析显示，Hcy（OR 4.165， 95％CI 1.138～15.249，P =0.031）是LA患者肾功能不全的危险因素。结论 Hcy是LA患者肾功能不全的危险因素，肾功能不全可能通过影响血浆Hcy水平从而参与LA的发生发展。

文章导读： 本文对LA、肾功能不全与Hcy之间的关系进行了多因素分析和相关性分析，发现血浆Hcy升高是LA合并肾功能不全的危险因素。

关键词: 脑白质疏松; 肾功能不全; 同型半胱氨酸

Abstract:

Objective To examine the relationship of the level of plasma Hcy with renal dysfunction in patients with leukoaraiosis (LA). Methods According to the renal function, the patients were divided into renal dysfunction group (n =112) and normal control group (n =74). Demographic information such as sex, age, and past history were collected. The blood Cr, BUN, UA, Hcy, HbA1c, TC, LDL-C were measured. The degree of LA was measured by Fazekas scale according to MRI imaging. Results A total of 186 patients with LA were enrolled in this study. (1) The BUN (P =0.001), Cr (P =0.000), UA (P =0.000) and Hcy levels in renal dysfunction group were significantly higher than those in control group (P =0.000), and the Fazekas score was significantly higher than that of control group (P =0.04). (2) The correlation analysis showed that plasma Hcy level were positively correlated with the Fazekas score (r =0.202, P =0.027), the level of blood Cr (r =0.458, P =0.000), UA (r =0.229, P =0.010) and BUN (r =0.178, P =0.046). (3) Multivariate logistic regression analysis showed that plasma Hcy level (OR 4.165, 95%CI 1.138-15.249, P =0.031) was an independent risk factor of renal dysfunction in patients with LA . Conclusions Plasma Hcy level may be an independent risk factor of renal dysfunction in patients with LA, and renal dysfunction may be involved in the development of LA by affecting blood Hcy level.

Key words: Leukoaraiosis; Renal dysfunction; Homocysteine

徐畅，徐俊，张志宇，孙奕，黄丹青，王变荣. 脑白质疏松患者肾功能不全与血浆同型半胱氨酸的相关性研究[J]. 中国卒中杂志, 2019, 14(02): 106-110.

XU Chang, XU Jun,ZHANG Zhi-Yu, SUN Yi, HUANG Dan-Qing, WANG Bian-Rong. Relationship of Homocysteine with Renal Dysfunction in Patients with Leukoaraiosis[J]. Chinese Journal of Stroke, 2019, 14(02): 106-110.

参考文献

[1] HACHINSKI V C，POTTER P，MERSKEY H.

Leukoaraiosis[J]. Arch Neurol，1987，44（1）：21-23.

[2] HENNINGER N，KHAN M A，ZHANG J，et al.

Leukoaraiosis predicts cortical infarct volume after

distal middle cerebral artery occlusions[J]. Stroke，

2014，45（3）：689-695.

[3] LIU D，DING H，LIU S，et al. Estimated glomerular

filtration rate decline in 567 patients with acute

stroke[J]. Scand J Urol Nephrol，2012，46（2）：142-

147.

[4] TOYODA K，NINOMIYA T. Stroke and cerebrovascular

diseases in patients with chronic kidney

disease[J]. Lancet Neuro，2014，13（8）：823-833.

[5] TURK M，ZUPAN M，ZALETEL M，et al. Carotid

arterial hemodynamic in ischenmic levkoaraiosis

suggests hypoperfusion mechanism[J]. Eur Neurol，

2015，73（56）：310-315.

[6] THE LADIS STUDY GROUP，POGGESI A，

PANTONI L，et al. 2001-2011：a decade of the

LADIS（Leukoaraiosis And DISability）Study：what

have we learned about white matter changes and

small-vessel disease?[J]. Cerebrovasc Dis，2011，32

（6）：577-588.

[7] DEBETTE S，MARKUS H S. The clinical

importance of white matter hyperintensities on brain

magnetic resonance imaging：systematic review and meta- analysis[J/OL]. BMJ. 2010，341：c3666. https：

//doi.org/10.1136/bmj.c3666.

[8] VERHAAREN F J，VERNOIJ M W，DE BOER R，

et al. High blood pressure and cerebral white matter

lesion progression in the general population[J].

Hypertension，2013，61（6）：1354-1359.

[9] FAZEKAS F，KLEINERT R，OFFENBACHER H，

et al. Pathologic correlates of incidental MRI white

matter signal hyperintensities[J]. Neurology，1993，

43（9）：1683-1689.

[10] CENSORI B，PARTZIGUIAN T. Plasma

homocysteine and severe white matter disease[J].

Neurol Sci，2007，28（5）：259-263.

[11] CHEN Y F，LI PL，ZOU A P. Effect of

hyperhomocysteinemia on plasma or tissue

adenosine levels and renal function[J]. Circulation，

2002，106（10）：1275-1281.

[12] ROYBAL C N，YANG S，SUN C W，et al.

Homocysteine increases the expression of vascular

endothelial growth factor by a mechanism involving

endoplasmic reticulum stress and transcription factor

ATF4[J]. Biol Chem，2004，279（15）：14844-14852.

[13] NEMOTO S，TAKEDA K，YU Z X，et al. Role

for mitochondrial oxidants as regulators of cellular

metabolism[J]. Mol Cell Biol，2000，20（19）：7311-

7318.

[14] MAJORS A K，SENGUPTA S，WILLARD B，et al.

Homocysteine binds to [human plasma fibronectin

and inhibits its interaction with fibrin[J]. Arterioscler

Thromb Vasc Biol，2002，22（8）：1354-1359.

[15] KIRKLAND G，KHONG T，KATERELOS M，et

al. Heparinbinding epidermal growth factor-like

growth factor is expressed in the adhesive lesions of

experimental focal glomerular sclerosis[J]. Kidney

Int，1999，55（6）：2310-2321.

[16] PERNA A F，INGROSSO D，SATTA E，et al.

Homocysteine metabolism in renal failure[J]. Curr

Opin Clin Nutr Metab Care，2004，7（1）：53-57.

[17] JARDINE M J，KANG A，ZOUNGAS S，et al.

The effect of folic acid based homocysteine low on

cardiovascular events in people with kidney disease：

systematic review and meta-analysis[J/OL]. BMJ，

2012，344：e3533. https：//doi.org/10.1136/bmj.e3533.

[18] HALL S，GODDARD C，OPIO D，et al. Feasibility，

acceptability and potential effectiveness of Dignity

Therapy for older people in care homes：a phase II

randomized controlled trial of a brief palliative care

psychotherapy[J]. Palliat Med，2011，26（5）：703-712.

[19] 陆冰，刘洲，王俊贤，等. 不同分级脑白质疏松症患

者血清胱抑素C水平的临床意义[J]. 浙江医学，2018，

40（10）：1091-1093，1098.

[20] KHATRI M，WRIGHT C B，NICKOLAS T L，et

a1. Chronic kidney disease is associated with

white matter hyperintensity volume：the Northern

Manhattan Study（NOMAS）[J]. Stroke，2007，38

（12）：3121-3126.

[21] CHENG J X，ZHANG H Y，PENG Z K，et al.

Divergent topological networks in Alzheimer’s

disease：a diffusion kurtosis imaging analysis[J/

OL]. Transl Neurodegener，2018，7：10. https：//doi.

org/10.1186/s40035-018-0115-y.

[22] TOYODA K. Cerebral small vessel disease and chronic

kidney disease[J]. Stroke，2015，17（1）：31-37.

[23] FENG C，BAI X，XU Y，et al. Hyperhomocysteinemia

associates with small vessel disease more closely

than large vessel disease[J]. Int J Med Sci，2013，10

（4）：408-412.

[24] 刘翠梅. 脑白质疏松症危险因素的相关分析研究[D].

苏州：苏州大学，2016.

[25] SPLAVER A，LAMAS G A，HENNEKENS C H.

Homocysteine and cardiovascular disease：biological

mechanisms，observational epidemiology，and the

need for randomized trials[J]. Am Heart J，2004，148

（1）：34-40.